Neuphoria Therapeutics’ (NEUP) Buy Rating Reaffirmed at HC Wainwright

Neuphoria Therapeutics (NASDAQ:NEUP)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $21.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 184.94% from the company’s previous close.

Separately, Wall Street Zen upgraded Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $21.00.

Neuphoria Therapeutics Stock Performance

Shares of NASDAQ NEUP traded up $0.03 during midday trading on Tuesday, hitting $7.37. 6,543 shares of the company’s stock were exchanged, compared to its average volume of 228,311. The company’s 50 day moving average price is $7.46 and its 200 day moving average price is $6.14. Neuphoria Therapeutics has a 12 month low of $2.12 and a 12 month high of $12.55.

Institutional Investors Weigh In On Neuphoria Therapeutics

A hedge fund recently bought a new stake in Neuphoria Therapeutics stock. Jane Street Group LLC bought a new position in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,311 shares of the company’s stock, valued at approximately $46,000. Jane Street Group LLC owned about 0.82% of Neuphoria Therapeutics at the end of the most recent reporting period. 15.90% of the stock is owned by hedge funds and other institutional investors.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.